A Randomized, Double-blind, Placebo-Controlled, 3-Period Crossover Study Followed by 1 Open-label Comparator Period to Evaluate Central Nervous System Pharmacodynamic Activity of TAK-653 in Healthy Volunteers Using Transcranial Magnetic Stimulation
Latest Information Update: 22 Mar 2021
At a glance
- Drugs Osavampator (Primary) ; Ketamine
- Indications Depressive disorders
- Focus Pharmacodynamics
- Sponsors Neurocrine Biosciences
Most Recent Events
- 25 Jun 2019 Status changed from recruiting to completed.
- 10 Jun 2019 Planned primary completion date changed from 30 May 2019 to 14 Jun 2019.
- 15 Feb 2019 Status changed from not yet recruiting to recruiting.